These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 8610104)

  • 1. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.
    Becker JC; Pancook JD; Gillies SD; Mendelsohn J; Reisfeld RA
    Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2702-7. PubMed ID: 8610104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein.
    Reisfeld RA; Gillies SD; Mendelsohn J; Varki NM; Becker JC
    Cancer Res; 1996 Apr; 56(8):1707-12. PubMed ID: 8620479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice.
    Sabzevari H; Gillies SD; Mueller BM; Pancook JD; Reisfeld RA
    Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9626-30. PubMed ID: 7937818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2.
    Pancook JD; Becker JC; Gillies SD; Reisfeld RA
    Cancer Immunol Immunother; 1996 Feb; 42(2):88-92. PubMed ID: 8620525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy.
    Xiang R; Lode HN; Dolman CS; Dreier T; Varki NM; Qian X; Lo KM; Lan Y; Super M; Gillies SD; Reisfeld RA
    Cancer Res; 1997 Nov; 57(21):4948-55. PubMed ID: 9354462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
    Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM
    Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy.
    Becker JC; Pancook JD; Gillies SD; Furukawa K; Reisfeld RA
    J Exp Med; 1996 May; 183(5):2361-6. PubMed ID: 8642346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
    Schanzer JM; Fichtner I; Baeuerle PA; Kufer P
    J Immunother; 2006; 29(5):477-88. PubMed ID: 16971804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells.
    Naramura M; Gillies SD; Mendelsohn J; Reisfeld RA; Mueller BM
    Immunol Lett; 1993 Dec; 39(1):91-9. PubMed ID: 8144194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of anti-ganglioside antibodies on the metastatic spread of intraocular melanomas in a nude mouse model of human uveal melanoma.
    Niederkorn JY; Mellon J; Pidherney M; Mayhew E; Anand R
    Curr Eye Res; 1993 Apr; 12(4):347-58. PubMed ID: 8319494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.
    Rosenberg SA; Mulé JJ; Spiess PJ; Reichert CM; Schwarz SL
    J Exp Med; 1985 May; 161(5):1169-88. PubMed ID: 3886826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the growth of human melanoma metastases in nude mice by melanoma-specific murine monoclonal antibody.
    Abdel-Wahab ZA; Darrow TL; Vervaert CE; Giannopoulou AA; Li W; Seigler HF
    Surg Oncol; 1992 Apr; 1(2):115-25. PubMed ID: 1341242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy.
    Dolman CS; Mueller BM; Lode HN; Xiang R; Gillies SD; Reisfeld RA
    Clin Cancer Res; 1998 Oct; 4(10):2551-7. PubMed ID: 9796990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.
    Eisenthal A; Cameron RB; Uppenkamp I; Rosenberg SA
    Cancer Res; 1988 Dec; 48(24 Pt 1):7140-5. PubMed ID: 3263900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor alpha.
    Yang SC; Fry KD; Grimm EA; Roth JA
    Arch Surg; 1990 Feb; 125(2):220-5. PubMed ID: 2137327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy.
    Lode HN; Xiang R; Dreier T; Varki NM; Gillies SD; Reisfeld RA
    Blood; 1998 Mar; 91(5):1706-15. PubMed ID: 9473237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
    Lode HN; Xiang R; Varki NM; Dolman CS; Gillies SD; Reisfeld RA
    J Natl Cancer Inst; 1997 Nov; 89(21):1586-94. PubMed ID: 9362156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.